RESUMO
BACKGROUND: Although more than a year past since COVID-19 was defined, there is no specific treatment yet. Since COVID-19 management differs over time, it is hard to determine which therapy is more efficacious. In this study, we aimed to evaluate the efficacy of the regimen with Favipiravir (FPV) and determine if the timing of FPV addition offers any improvement. METHODS: A retrospective observational case-controlled cohort study was performed between March and September 2020, including adults with COVID-19 in a single-center in Turkey. We categorized patients into age-sex matched three groups, group 1 (n = 48) and group 2 (n = 48) included patients treated with the combination of FPV plus Hydroxychloroquine (HQ) early and late, respectively. Group 3 (n = 48) consisted of patients on HQ monotherapy. In Group 2, if the respiratory or clinic condition had not improved sufficiently, FPV was added on or after day 3. RESULTS: We found that starting FPV early had an impact on PCR negativity and the progression of the disease. 'No progression' was defined as the absence of a new finding in the control radiological examination and the absence of accompanying clinical deterioration. Also, the decrease in C-reactive protein (CRP) was greater in Group 1 than Group 3 (p < 0.001). However, we found that early initiation of FPV treatment did not have a positive effect on the estimated survival time. CONCLUSIONS: According to this retrospective study results, we believe that for better clinical outcomes, FPV treatment should be started promptly to enhance antiviral effects and improve clinical outcomes.
Assuntos
Amidas/uso terapêutico , Antivirais/uso terapêutico , Tratamento Farmacológico da COVID-19 , Pirazinas/uso terapêutico , SARS-CoV-2/efeitos dos fármacos , Idoso , COVID-19/fisiopatologia , COVID-19/virologia , Estudos de Casos e Controles , Esquema de Medicação , Feminino , Humanos , Hidroxicloroquina/uso terapêutico , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , SARS-CoV-2/isolamento & purificação , Resultado do TratamentoRESUMO
In this study, the in vitro activity of carvacrol on 100 clinical isolates of Candida albicans was evaluated by determining the minimum inhibitory concentrations (MICs). Susceptibility of clinical isolates of C. albicans to carvacrol was determined by broth microdilution method. Carvacrol was active in vitro against all strains of C. albicans, with MICs ranging from 0.125% to 0.004%. MIC(50) and MIC(90) values of carvacrol were observed at 0.064 and 0.125 mg mL(-1), respectively. MIC and MFC values were similar for most of the tested strains. These results indicated that carvacrol inhibited the growth of C. albicans, implying its potential use in the topical treatment of C. albicans infections.